- Conditions
- Chemotherapy-induced Peripheral Neuropathy
- Interventions
- Memantine XR-pregabalin combination therapy
- Drug
- Lead sponsor
- Saint John's Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Santa Monica, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- SSRI (escitalopram or sertraline), Extended-Release Memantine, Placebo
- Drug
- Lead sponsor
- Jeffrey Miller
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Brain Metastases
- Interventions
- Memantine -Twice Daily or Extended Release, WBRT utilizing the PRDR technique
- Drug · Radiation
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 2
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Autistic Disorder, Autism, Asperger's Disorder, Asperger Syndrome, Autism Spectrum Disorders, Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS)
- Interventions
- Memantine Hydrochloride (HCl), Placebo capsules
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 64
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more
- Conditions
- Alzheimer's Disease
- Interventions
- Idalopirdine 60 mg
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,463 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 64
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more
- Conditions
- Brain Tumor
- Interventions
- Memantine, Raloxifene
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Autism
- Interventions
- Memantine - Extended Release (ER), Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more
- Conditions
- Brain Metastases
- Interventions
- MA-WBRT (Memory Avoidance Whole Brain Radiation Therapy (MA-WBRT)), HA-WBRT (Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT)), Memantine
- Radiation · Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
- Interventions
- Memantine Hydrochloride (HCl)
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 747 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 68
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
- Conditions
- Alzheimer's Disease
- Interventions
- SUVN-502, Placebo, Donepezil, Memantine
- Drug
- Lead sponsor
- Suven Life Sciences Limited
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 564 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 71
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more
- Conditions
- Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
- Interventions
- Memantine Hydrochloride (HCl)
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 906 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 72
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 63 more
- Conditions
- Autism, Pediatric Autism
- Interventions
- Memantine HCl
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more